Revenue Recognition (Tables)

3 Months Ended

Mar. 31, 2023

Revenue from Contract with Customer [Abstract]

Schedule of net revenue from collaborative arrangements

Net revenue recognized under our GSK Agreements was as follows:

	Three Months Ended March 31,
(In thousands)	2023			2022
Royalties    - RELVAR/BREO	$	50,883		$	55,764
Royalties    - ANORO		9,431			8,442
Royalties    - TRELEGY		—			29,309
Total royalties		60,314			93,515
Less: amortization of capitalized fees    paid		(3,456	)		(3,456	)
Total net royalty revenue	$	56,858		$	90,059